Phase II trial of MVE-II in metastatic malignant melanoma.
MVE-II, a low molecular weight fraction of pyran copolymer was utilized in a Phase II trial in patients with metastatic malignant melanoma. A total of 15 patients were investigated and no clinical responses or immunologic responses were observed. We concluded that MVE-II is not an active agent in malignant melanoma.
D000328:Adult; D000368:Aged; D000920:Antibody-Dependent Cell Cytotoxicity; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D006801:Humans; D007109:Immunity; D007958:Leukocyte Count; D008214:Lymphocytes / Q000276:immunology; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D009000:Monocytes / Q000276:immunology; D011108:Polymers / Q000627:therapeutic use*; D011713:Pyran Copolymer / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000145:classification / Q000276:immunology
D011108:Polymers; D011713:Pyran Copolymer